Log in | Register

The European Society of Intensive Care Medicine (ESICM) and the Surviving Sepsis Campaign (SSC)

V. Marco Ranieri| Rui P. Moreno| Andy Rhodes
ESICM Statement
Volume 33, Issue 3 / March , 2007

Pages 423 - 425

No abstract available.

References

  1. Slade E, Tamber PS, Vincent JL (2003) The Surviving Sepsis Campaign: raising awareness to reduce mortality. Crit Care 7:1–2
    • View reference on PubMed
    • View reference on publisher's website
  2. Dellinger RP, Carlet JM, Masur H et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536–555
  3. Eichacker PQ, Natanson C, Danner RL (2006) Surviving Sepsis: practice guidelines, marketing campaigns, and Eli-Lilly. N Engl J Med 355:1640–1642
    • View reference on PubMed
    • View reference on publisher's website
  4. Wiedermann CJ (2005) Bioethics, the Surving Sepsis Campaign, and the industry. Wien Klin Wochenschr 117:442–444
    • View reference on PubMed
    • View reference on publisher's website
  5. Singer M (2006) The Surviving Sepsis guidelines: evidence-based... or evidence-biased? Crit Care Resuscitation 8:244–245
  6. Weinert CR, Gross CR, Marinelli WA (2003) Impact of randomized trial results on acute lung injury ventilator therapies in teaching hospitals. Am J Respir Crit Care Med 167:1297–1298
    • View reference on publisher's website
  7. Brun-Buisson C, Minelli C, Bertolini G et al. (2004) Epidemiology and outcome of acute lung injury in European intensive care units. Results of the ALIVE study. Intensive Care Med 30:4–6
  8. Landucci D (2004) The Surviving Sepsis guidelines: “lost in translation”. Crit Care Med 32:1598–600
    • View reference on PubMed
    • View reference on publisher's website
  9. Mackenzie AF (2005) Activated protein C: Do more survive? Intensive Care Med 31:1624–1626
  10. Wiedermann CJ (2006) When a single pivotal trial should not be enough: the case of drotrecogin-alfa (activated). Intensive Care Med 32:604
  11. Carlet J (2004) A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker. Intensive Care Med 30:994
  12. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL (2003) Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894–903
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement